Genmab — Maj 2018
-
Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. Lille studie, men 100% ORR. https://link.springer.com/article/10.1007/s12185-017-2390-2
-
the addition of daratumumab to Rd led to prolonged PFS with increased and deeper responses compared with Rd alone in both East Asian patients and Japanese patients from POLLUX, consistent with findings in the international POLLUX population. Given the recent approval of daratumumab in combination with lenalidomide and dexamethasone as a new treatment option in Japan13, these findings suggest that this regimen is a new standard of care for Japanese patients with RRMM
-
Tak gentogen. Jans optimisme med Japan er velbegrundet.
-
Q&A starter om 5 minutter.
-
Tusinde tak for mange gode og skarpe spørgsmål til alle.
-
@jkj, lige mine tanker
-
Netop. Det var meget positivt.
-
Jeps.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind